New drug combo aims to shrink oral cancers before surgery
NCT ID NCT07686575
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This trial investigates whether adding ivonescimab—a drug that targets both PD-1 and VEGF—to standard chemotherapy can shrink locally advanced oral or oropharyngeal cancers before surgery. About 20 adults with resectable stage II–IVA disease will receive two cycles of the combination, then undergo surgery. The main goal is to see how many patients have a significant tumor reduction, with secondary aims including patterns of tumor shrinkage and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ivonescimab (a bispecific antibody targeting PD-1 and VEGF) combined with paclitaxel and cisplatin or carboplatin
- What this could lead to
- If successful, this approach could shrink tumors before surgery, potentially making them easier to remove and improving long-term control of oral or oropharyngeal cancer.
- What could go wrong
- This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The combination therapy carries risks of side effects from chemotherapy and immunotherapy, including immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Stomatology, Zhujiang Hospital, Southern Medical University, Haizhu District, Guangzhou
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510282, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Department of Stomatology, Zhujiang Hospital, Southern Medical University,Haizhu District
RECRUITINGGuangzhou, Guangdong, 510282, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple swab predict who needs less radiation?
- Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
- Acupuncture timing may be key to preventing dry mouth in head and neck cancer patients
- New Vaccine-Drug combo aims to tame HPV throat cancer with less radiation
- New drug SKB571 takes on recurrent head and neck cancer
- New pill-chemo combo takes on hard-to-treat cancers